Biologic Predictors of Leiomyoma Treatment Outcomes

Status Completed

Clinical Trial Summary

The purpose of this study is to search for the hereditary (genetic) causes of uterine fibroids. Some women with uterine fibroids may have one or more genes that make them more likely to develop uterine fibroids. We are trying to identify these genes to better understand how and why uterine fibroids develop and to design better treatment options for women with uterine fibroids. This information may also help us to understand and treat other problems that may be caused by these genes.

Clinical Trial Description

There is little information to predict outcomes of leiomyoma therapies. It is clear that both environmental exposures and genetic predisposition influence disease manifestations. Our work has identified a new area of genetic linkage for leiomyomas from a genome wide scan. We therefore propose to prospectively collect biologic samples that will allow us to analyze gene/environment interactions of women enrolled in leiomyoma clinical trials or undergoing leiomyoma clinical treatments using the same methodology used previously. Specifically we will collect serum aliquots, genomic DNA and information using a genetic epidemiology questionnaire. In the short term we will also be able to use prospectively obtained information on epidemiologic and anthropomorphic data to characterize women undergoing treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01936493
Study type	Observational
Source	Mayo Clinic
Contact
Status	Completed
Phase	N/A
Start date	August 2009
Completion date	May 26, 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01441635` - Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids	Phase 2
Completed	`NCT00958334` - Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003	Phase 2
Withdrawn	`NCT04567589` - A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in Canada
Recruiting	`NCT05078307` - Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids	N/A
Recruiting	`NCT02283502` - Clinical Test of the MRgHIFU System on Uterine Fibroids	Phase 1
Completed	`NCT01739621` - Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200	Phase 2
Completed	`NCT01631903` - Extension of Study ZPV-200	Phase 2
Withdrawn	`NCT00768742` - Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study	N/A
Completed	`NCT00152256` - A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids	Phase 3
Not yet recruiting	`NCT03586947` - Association Between Vitamin D and the Risk of Uterine Fibroids	N/A
Completed	`NCT02925494` - An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids	Phase 3
Not yet recruiting	`NCT06055114` - Study on Vaginal Microecology and Cervical Local Immune Function in Patients With Uterine Fibroids of Childbearing Age
Terminated	`NCT05026502` - A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
Withdrawn	`NCT04567095` - A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada
Withdrawn	`NCT03699176` - Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids	Phase 3
Not yet recruiting	`NCT02884960` - Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization	N/A
Completed	`NCT02472184` - Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy	N/A
Completed	`NCT01452659` - Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids	Phase 2
Terminated	`NCT01555073` - Preemptive Analgesia Following Uterine Artery Embolization	Phase 4
Completed	`NCT01229826` - Magnetic Resonance Elastography (MRE) of Uterine Fibroids	N/A